Last reviewed · How we verify
Sclerosol (TALC)
Sclerosol (TALC) is a small molecule modality developed by Nobelpharma Co., Ltd. and currently owned by Sciarra Labs. It is approved for the treatment of inoperable secondary intractable pneumothorax and suppression of recurrence of malignant pleural effusions. Despite being off-patent, there are no generic manufacturers available. Key safety considerations include its use as a sclerosing agent, which can cause inflammation and fibrosis. Sclerosol (TALC) is used to induce scarring in the pleural space to prevent further fluid accumulation.
At a glance
| Generic name | TALC |
|---|---|
| Sponsor | Nobelpharma Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Inoperable secondary intractable pneumothorax
- Suppression of recurrence of malignant pleural effusions
Common side effects
- Fever
- Pain
Serious adverse events
- Empyema
- Pneumonia
- ARDS
- Bronchopleural fistula
- Hemoptysis
- Pulmonary emboli
- Myocardial infarction
- Asystolic arrest
- Subcutaneous empyema
- Adenocarcinoma of the chest wall
Key clinical trials
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1,PHASE2)
- Evaluation of Pine Bark Extract for Anti-fatigue Ergogenic Properties (NA)
- Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin Health and Reducing Signs of Aging on Healthy Adult Male and Female Subjects. (NA)
- Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in Pleurodesis (NA)
- Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis (PHASE3)
- Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (PHASE2)
- Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer (PHASE3)
- Intravenous Immunoglobulin and Prednisolone for RPL After ART. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |